CD38 and acute lymphoblastic leukemia: Our results presented here demonstrated the feasibility of CD38 CAR‐T/NK cell therapy against T‐ALL, expanding the application of CD38 CARs, which is also consistent with a recently published work.[44] In our study, CD38KO/KIEF1α CAR‐T cells efficiently eliminated T‐ALL cell lines and primary T‐ALL cells from patients in vitro and displayed potent antitumor activity in a mouse T‐ALL model.